{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:52:38Z","timestamp":1787021558076,"version":"build-2736575974"},"reference-count":14,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the comparative incidence of endoscopic gastroduodenal ulcers in patients with rheumatoid arthritis or osteoarthritis treated with celecoxib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>Quantitative systematic review of randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUBJECTS:<\/jats:title>\n                    <jats:p>Patients (n = 4632) with rheumatoid arthritis or osteoarthritis reported in five trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n                    <jats:p>Rate ratios, rate differences, and the number needed to harm were calculated for the incidence of endoscopically documented gastroduodenal ulcers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Pooled rate ratios (RRs) relative to placebo for endoscopic ulcers at 12 weeks were 1.96 (95% CI 0.85 to 4.55) for celecoxib 100 mg twice daily and 2.35 (95% CI 1.02 to 5.38) for celecoxib 200 mg twice daily. There was no significant difference in gastroduodenal ulcers at 12 weeks between celecoxib 200 mg twice daily and celecoxib 100 mg twice daily; the corresponding pooled RR was 1.21 (95% CI 0.62 to 2.38). In contrast, celecoxib 200 mg twice daily was associated with a significantly lower rate of gastroduodenal ulcers than was naproxen 500 mg twice daily at 12 weeks (RR 0.24; 95% CI 0.17 to 0.33). On average, for every seven patients treated with naproxen, one more had an endoscopic ulcer than if they were treated with celecoxib. Celecoxib 200 mg twice daily also had a significantly lower risk of endoscopic ulcers than did either modified-release diclofenac 75 mg twice daily at 24 weeks (RR 0.24; 95% CI 0.11 to 0.52) or ibuprofen 800 mg three \u00d7 daily at 12 weeks (RR 0.30; 95% CI 0.20 to 0.46).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Endoscopic studies have shown that celecoxib, at a wide range of doses, is associated with a lower incidence of gastroduodenal ulcers than are diclofenac, ibuprofen, or naproxen. The incidence rates of gastroduodenal ulcers associated with celecoxib were similar, although not equivalent, to placebo. Head-to-head comparisons suggest that, at the wide range of doses studied (100\u2013800 mg\/d), there are no dose-related increases in endoscopic gastroduodenal ulcers with celecoxib. The results of longer term comparative trials of celecoxib based on clinical outcomes are needed to determine celecoxib's ultimate risk\u2014benefit profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.10382","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T17:10:23Z","timestamp":1054660223000},"page":"829-834","source":"Crossref","is-referenced-by-count":21,"title":["Upper Gastroduodenal Ulceration in Arthritis Patients Treated with Celecoxib"],"prefix":"10.1177","volume":"35","author":[{"given":"Darren M","family":"Ashcroft","sequence":"first","affiliation":[{"name":"Darren M Ashcroft PhD, Prescribing Strategy Pharmacist, Department of Medicines Management, Keele University, Staffordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R","family":"Chapman","sequence":"additional","affiliation":[{"name":"Stephen R Chapman PhD, Professor of Prescribing Studies, Department of Medicines Management, Keele University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K","family":"Clark","sequence":"additional","affiliation":[{"name":"Wendy K Clark BPharm, Drug Information Pharmacist, Department of Medicines Management, Keele University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Millson","sequence":"additional","affiliation":[{"name":"David S Millson PhD, Professor of Medicines Management, Department of Medicines Management, Keele University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2001,7,1]]},"reference":[{"key":"bibr1-aph.10382","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-4-199508150-00001"},{"key":"bibr2-aph.10382","doi-asserted-by":"publisher","DOI":"10.3111\/199902045055"},{"key":"bibr3-aph.10382","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12154-2"},{"key":"bibr4-aph.10382","first-page":"1","volume":"7","year":"2000","journal-title":"Bandolier"},{"key":"bibr5-aph.10382","volume-title":"The handbook of research synthesis","author":"Cooper H","year":"1994"},{"key":"bibr6-aph.10382","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"bibr7-aph.10382","unstructured":"United States Food and Drug Administration. FDA Draft label for celecoxib. 1998. (www.fda.gov\/cder\/foi\/label\/1998\/20998lbl.pdf)."},{"key":"bibr8-aph.10382","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1921"},{"key":"bibr9-aph.10382","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02332-6"},{"key":"bibr10-aph.10382","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"bibr11-aph.10382","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70358-6"},{"key":"bibr12-aph.10382","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1929"},{"key":"bibr13-aph.10382","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02194.x"},{"key":"bibr14-aph.10382","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7256.291"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.10382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.10382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:04:58Z","timestamp":1777374298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.10382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":14,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1345\/aph.10382"],"URL":"https:\/\/doi.org\/10.1345\/aph.10382","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}